Antithrombin alfa
ATryn (antithrombin alfa) is a protein pharmaceutical. Antithrombin alfa was first approved as Atryn on 2006-07-28. It has been approved in Europe to treat antithrombin III deficiency.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
37 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Antithrombin iii deficiency | D020152 | HP_0001976 | D68.59 | 2 | 2 | 3 | 2 | 1 | 10 |
| Acute coronary syndrome | D054058 | EFO_0005672 | — | — | — | 1 | — | 1 | |
| Aortic valve stenosis | D001024 | EFO_0000266 | Q25.1 | — | — | — | 1 | — | 1 |
| Aortic valve insufficiency | D001022 | EFO_0007148 | — | — | — | 1 | — | 1 | |
| Mitral valve insufficiency | D008944 | HP_0001653 | — | — | — | 1 | — | 1 | |
| Mitral valve stenosis | D008946 | EFO_0007372 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Disseminated intravascular coagulation | D004211 | HP_0005521 | D65 | — | 1 | 3 | — | — | 4 |
| Cardiopulmonary bypass | D002315 | 2 | — | 1 | — | — | 3 | ||
| Pre-eclampsia | D011225 | EFO_0000668 | O14 | — | — | 2 | — | — | 2 |
| Extracorporeal membrane oxygenation | D015199 | — | 1 | 1 | — | — | 1 | ||
| Hemophilia a | D006467 | EFO_0007267 | D66 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Covid-19 | D000086382 | U07.1 | — | 2 | — | — | 1 | 3 | |
| Reperfusion injury | D015427 | 1 | 1 | — | — | — | 2 | ||
| Coronary artery bypass | D001026 | EFO_0003776 | — | 1 | — | — | — | 1 | |
| Respiratory distress syndrome | D012128 | EFO_1000637 | J80 | — | 1 | — | — | — | 1 |
| Hepatic veno-occlusive disease | D006504 | K76.5 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Congenital heart defects | D006330 | HP_0001627 | Q24.9 | 1 | — | — | — | — | 1 |
| Postoperative hemorrhage | D019106 | 1 | — | — | — | — | 1 | ||
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | 1 | — | — | — | — | 1 |
| Healthy volunteers/patients | — | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | ANTITHROMBIN ALFA |
| INN | antithrombin alfa |
| Description | Antithrombin-III precursor (ATIII) (PRO0309) |
| Classification | Protein |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201554 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | AWV6I5L6H2 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 101 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
17 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more